Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Tobira Therapeutics to Participate in Two Conferences in September

Tobira Therapeutics,Inc.
Posted on: 01 Sep 16

Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the following conferences in September.

  • Rodman & Renshaw 18th Annual Global Investment Conference
    • Presentation date: Tuesday September 13, 2016
    • Presentation time: 2:55 p.m. ET
  • Aegis Capital Corp 2016 Growth Conference
    • Presentation date: Wednesday, September 21, 2016
    • Presentation time: 2:30 p.m. PT

A live webcast and 30-day archive of these presentations will be available at

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

View source version on

Business Wire

Last updated on: 01/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.